News Releases Keyword Search Year None202420232022202120202019201820172016 Jul-20-2020 Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Jun-30-2020 Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia Jun-30-2020 Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma May-20-2020 Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules May-19-2020 Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting May-07-2020 Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results May-01-2020 Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update Mar-16-2020 Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results Mar-11-2020 Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update Mar-11-2020 Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma Pagination First page « first Previous page ‹ previous … Page 9 Page 10 Page 11 Page 12 Current page 13 Page 14 Page 15 Page 16 Page 17 Next page next › Last page last »